1）Turner D, Ricciuto A, Lewis A, et al. STRIDE-II：An update on the selecting therapeutic targets in inflammatory bowel disease（STRIDE）initiative of the International Organization for the Study of IBD（IOIBD）：determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160：1570-1583, 2021
2）厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」（久松班）．潰瘍性大腸炎・クローン病診断基準・治療指針 令和5年度改訂版．令和5年度分担研究報告書，p 5, 2024
3）Truelove SC, Witts LJ. Cortisone in ulcerative colitis：final report on a therapeutic trial. Br Med J 2：1041-1048, 1955
4）Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87：971-976, 1992
5）Rachmilewitz D. Coated mesalazine（5-aminosalicylic acid）versus sulphasalazine in the treatment of active ulcerative colitis：a randomised trial. BMJ 298：82-86, 1989
6）van Hees PA, van Elteren PH, van Lier HJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 21：279-286, 1980
7）Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12：439-447, 1991
8）Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 52：561-571, 1930
9）Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11：707-712, 2005
10）Kuriyama M, Kato J, Takemoto K, et al. Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test. World J Gastroenterol 16：1110-1114, 2010
11）Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemi test. Am J Gastroenterol 108：83-89, 2013
12）Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol 110：873-880, 2015
13）Fagerhol MK, Dale I, Anderson T. Release and quantitation of a leucocyte derived protein（L1）. Scandinavian Journal of Haematology 24：393-398, 1980
14）Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients：a systematic review and meta-analysis. Am J Gastroenterol 110：802-819, 2015
15）D'Amico F, Nancey S, Danese S, et al. A practical guide for faecal calprotectin measurement：myths and realities. J Crohns Colitis 15：152-161, 2021
16）Molander P, FärkkiläM, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis 9：33-40, 2015
17）Shinzaki S, Matsuoka K, Tanaka H, et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab：PLANET study. J Gastroenterol 56：560-569, 2021
18）Haupt H, Baudner S. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2- glycoprotein from human serum（author's Transl）. Hoppe Seylers Z Physiol Chem 358：639-646, 1977
19）Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 18：2169-2179, 2012
20）Shinzaki S, Matsuoka K, Iijima H, et al. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J Crohns Colitis 11：84-91, 2017
21）Shimoyama T, Yamamoto T, Yoshiyama S, et al. Leucine-rich alpha-2 glycoprotein is a reliable serum biomarker for evaluating clinical and endoscopic disease activity in inflammatory bowel disease. Inflamm Bowel Dis 29：1399-1408, 2023
22）Takenaka K, Kitazume Y, Kawamoto A, et al. Serum leucine-rich α2 glycoprotein：a novel biomarker for transmural inflammation in Crohn's disease. Am J Gastroenterol 118：1028-1035, 2023
23）Okayasu I, Ohnishi H, Sarandi I, et al. Significant increase of prostaglandin E-major urinary metabolite in male smokers：a screening study of age and gender differences using a simple radioimmunoassay. J Clin Lab Anal 28：32-41, 2014
24）Arai T, Arihiro S, Matsuura T, et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis 20：1208-1216, 2014
25）Sakurai T, Akita Y, Miyashita H, et al. Prostaglandin E-major urinary metabolite diagnoses mucosal healing in patients with ulcerative colitis in remission phase. J Gastroenterol Hepatol 37：847-854, 2022
26）Ishida N, Sugiura K, Miyazu T, et al. Prostaglandin E-major urinary metabolite predicts relapse in patients with ulcerative colitis in clinical remission. Clin Transl Gastroenterol 11：e00289, 2020
27）Ishida N, Matsuura T, Asai Y, et al. Predicting ulcerative colitis relapse in clinical remission with fecal immunochemical occult blood test or prostaglandin e-major urinary metabolite. Clin Transl Gastroenterol 13：e00501, 2022
28）Hagiwara S, Abe N, Hosoi K, et al. Utility of a rapid assay for prostaglandin E-major urinary metabolite as a biomarker in pediatric ulcerative colitis. Sci Rep 13：9898, 2023
29）Duerr RH, Targan SR, Landers CJ, et al. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitis/diarrheal illnesses. Gastroenterology 100：1590-1596, 1991
30）Takedatsu H, Mitsuyama K, Fukunaga S, et al. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol 2018 doi：10.1111/jgh.14140［Epub ahead of print］
31）Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis. Gastroenterology 160：2383-2394, 2021
32）Livanos AE, Dunn A, Fischer J, et al. Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164：619-629, 2023
ログイン
ランキング
お知らせ
ログイン
